Hitherto ... indeed for many decades, survival rates for this particularly aggressive - hard to treat - form of cancer have remained practically unchanged.

However, at last, there is [some] hope of "light at the end of
the tunnel", due to trials using a combination of the standard chemotherapy drug, gemacitabine with capecitabine on 732
hospital patients in Sweden France & Germany.

www.bbc.co.uk/news/health-36444413

certainly looks promising. Especially when there're claimed
 to be no notable differences in side effects arising.